Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
File(s)
Author(s)
Type
Journal Article
Abstract
Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication.
Date Issued
2015-10-09
Date Acceptance
2015-08-27
Citation
Nature Communications, 2015, 6, pp.1-9
ISSN
2041-1723
Publisher
Nature Publishing Group
Start Page
1
End Page
9
Journal / Book Title
Nature Communications
Volume
6
Copyright Statement
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
License URL
Sponsor
Wellcome Trust
Medical Research Council (MRC)
Identifier
https://www.nature.com/articles/ncomms9495
Grant Number
069598/Z/02/Z
MR/N001265/1
Subjects
Science & Technology
Multidisciplinary Sciences
Science & Technology - Other Topics
HLA CLASS-I
ANTIRETROVIRAL THERAPY
INFECTED INDIVIDUALS
DISEASE PROGRESSION
T-CELLS
DETERMINANTS
POPULATION
EXPRESSION
MORTALITY
RESPONSES
Anti-HIV Agents
Biomarkers
CD4 Lymphocyte Count
HIV Infections
HIV-1
Humans
Viral Load
Withholding Treatment
Humans
HIV-1
HIV Infections
Anti-HIV Agents
CD4 Lymphocyte Count
Withholding Treatment
Viral Load
Biomarkers
Publication Status
Published
Article Number
8495
Date Publish Online
2015-10-09